Industrial Impact, Medical

Lentivirus production study in the scale-X™ fixed-bed bioreactor

April 24, 2023

Lentivirus production
Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Spotlight

Hookipa Biotech AG

Hookipa Biotech develops prophylactic and therapeutic vaccines for the prevention and treatments in oncology and for multiple infectious diseases. The company brings together experienced scientists, a diversified management team and a strong financial support to tackle the central challenges of cancer and immunology. Here at Hookipa our energy is sincere, we are motivated and together we can develop solutions for patients in need that don´t benefit from current therapies.

OTHER WHITEPAPERS
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Read More
news image

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More
news image

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Read More
news image

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More
news image

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Read More
news image

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Read More

Spotlight

Hookipa Biotech AG

Hookipa Biotech develops prophylactic and therapeutic vaccines for the prevention and treatments in oncology and for multiple infectious diseases. The company brings together experienced scientists, a diversified management team and a strong financial support to tackle the central challenges of cancer and immunology. Here at Hookipa our energy is sincere, we are motivated and together we can develop solutions for patients in need that don´t benefit from current therapies.

Events